Cargando…

Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma

BACKGROUND: Nimotuzumab exerts its antitumor effect (mainly antiproliferative, proapoptotic, and antiangiogenic) by blocking the epidermal growth factor receptor overexpressing between 30 and 95% in pancreatic tumors cells. METHODS: A prospective, nonrandomized, uncontrolled, open-label, and multice...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sánchez, Yamirka, Concepción, Martha L., Amador, Yohan, Piriz, Angel, Rabassa, René, Leyva, Ariel, Arguelles, Odalys, Leblanch, Lisett, Moret, Sheyla, Rivero, Gilberto, Vasallo, Ana L., Martorell, Beatriz, Guerra, Pedro P., Valls, Ana R., Sánchez, Lisset, Saumell, Yaimarelis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162878/ https://www.ncbi.nlm.nih.gov/pubmed/37152586 http://dx.doi.org/10.1155/2023/1496072

Ejemplares similares

Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
por: González Fernández, Sandra, et al.
Publicado: (2022)

Validation of Instruments for Assessing Drug Safety Management During the Conduction of Clinical Trials
por: Saumell, Yaimarelis, et al.
Publicado: (2017)

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
por: Garrido, Greta, et al.
Publicado: (2017)

Nimotuzumab for COVID-19: case series
por: Abdo Cuza, Anselmo A, et al.
Publicado: (2021)

Affinity-matured variants derived from nimotuzumab keep the original fine specificity and exhibit superior biological activity
por: Tundidor, Yaima, et al.
Publicado: (2020)

Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment
por: Londres, Henrry Diaz, et al.
Publicado: (2022)

Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario
por: Diaz, Henrry, et al.
Publicado: (2022)

Profile of nimotuzumab in the treatment of high-grade glioma
por: Yang, Qun-ying, et al.
Publicado: (2015)

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
por: Crombet Ramos, Tania, et al.
Publicado: (2020)

Biodistribution and Tumor Uptake of (67)Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft
por: Izquierdo-Sánchez, Vanessa, et al.
Publicado: (2018)

Arquetipos oral-traumáticos y cósmicos en las décimas de Odalys Leyva Rosabal /
por: Leyva Rosabal, Odalys, 1969-
Publicado: (2005)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

Bioinformatic Analysis of Hepatocellular Carcinoma Cell Lines to the Efficacy of Nimotuzumab
por: Wang, Yu, et al.
Publicado: (2021)

The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
por: Boland, William, et al.
Publicado: (2010)

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects
por: Perez, Rolando, et al.
Publicado: (2011)

Prostate specific antigen change after administration of nimotuzumab in prostate cancer
por: Chaiyasit, Kamon, et al.
Publicado: (2013)

Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma
por: Li, Zhanzhan, et al.
Publicado: (2017)

Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
por: Huang, Jianfeng, et al.
Publicado: (2018)

Time profile of nimotuzumab for enhancing radiosensitivity of the Eca109 cell line
por: Li, Jiancheng, et al.
Publicado: (2019)

Nimotuzumab as Additional Therapy for GLIOMA in Pediatric and Adolescent: A Systematic Review
por: Parenrengi, Muhammad A, et al.
Publicado: (2022)

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
por: Huang, Yanping, et al.
Publicado: (2023)

Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities
por: Diaz-Miqueli, Arlhee, et al.
Publicado: (2013)

Use of nimotuzumab in the patient with G-6-PD deficiency: The first world report
por: Wiwanitkit, Viroj
Publicado: (2013)

Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model
por: Bhuvaneswari, Ramaswamy, et al.
Publicado: (2015)

Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma
por: Fei, Zhaodong, et al.
Publicado: (2020)

Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Thai Hoa, Nguyen Thi, et al.
Publicado: (2020)

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

Induction chemotherapy plus nimotuzumab followed by concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma
por: Song, Xinmao, et al.
Publicado: (2019)

Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma
por: Zong, Jing-Feng, et al.
Publicado: (2021)

Efficacy and safety of nimotuzumab combined with chemoradiotherapy in the treatment of locally advanced cervical cancer
por: Zhang, Lei, et al.
Publicado: (2022)

Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers
por: Bernhard, Wendy, et al.
Publicado: (2023)

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial
por: Yuan, Jing-Jing, et al.
Publicado: (2022)

Cost-utility analysis of using nimotuzumab in end-stage cancerous patient: Is it too expensive?
por: Chaiyasit, Kamon, et al.
Publicado: (2013)

Study on chemotherapeutic sensitizing effect of nimotuzumab on different human esophageal squamous carcinoma cells
por: YANG, XIAOYU, et al.
Publicado: (2016)

Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
por: Zhai, Rui-ping, et al.
Publicado: (2015)

Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer
por: Han, Xinghua, et al.
Publicado: (2017)

Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis
por: Liu, Zhi-gang, et al.
Publicado: (2016)

(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
por: Chekol, Rufael, et al.
Publicado: (2018)

Nimotuzumab combined with chemotherapy as first‐line treatment for advanced lung squamous cell carcinoma
por: Si, Xiaoyan, et al.
Publicado: (2018)

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d55reqhbbvrrl7a0tilb80flmq